资讯

Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...
The National Alzheimer’s Coordinating Center unites the collections of the neuropathology cores at 27 NIA-funded AD Research Centers into a single database. It contains records on 13,000 brains, 3,000 ...
An interactive timeline of the evolution of Alzheimer's Disease research.
Dozens of rodents have been generated that model various aspects of ALS, like motor impairment or degeneration of motor neurons. No model recapitulates the human disease perfectly. By organizing ...
Plasma p-tau217 has rapidly pushed to the forefront of Alzheimer’s biomarkers, proving as accurate at predicting plaques as amyloid PET. However, it is less clear how well this blood marker stacks up ...
As the baby boom generation reaches its hopefully golden years, scientists have been projecting a doubling of dementia cases in the U.S. by 2050, alarming health care agencies, the public, and health ...
Lecanemab binds protofibrils more tightly than fibrils, perhaps explaining lower ARIA rate. Use of plasma biomarkers brings down trial screening cost. Lecanemab has been selected for the first amyloid ...
Species: Mouse Genes: SNCA Modification: SNCA: Transgenic Disease Relevance: Parkinson's Disease Strain Name: B6;DBA-Tg(Thy1-SNCA)61Ema Genetic Background: (C57BL/6 x DBA/2)F1 (strain of origin) ...
Do you know a conference you think we should list? Let us know by sending us an email with the details to conferences@alzforum.org.
The Senescence Accelerated Mouse-Prone 8 (SAMP8) is a naturally occuring mouse line that displays a phenotype of accelerated aging. While maintaining an inbred AKR/J line in the early 1970's, ...
The slight slowing of cognitive decline achieved by Leqembi and perhaps by Aduhelm has revived debate around how much change is needed to be “clinically meaningful.” Two recent papers—one a report ...
Early onset familial Alzheimer disease (eFAD) is hereditary and marked by Alzheimer disease symptoms that appear at an unusually early age. Symptoms can start in a person's thirties, forties, and ...